Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.92 Analyst target: $4.16 Upside: 352.76%
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company is headquartered in Singapore.
See the full interactive analysis & chart →Informational only — not investment advice.